Semaglutide generics 2026: India launches, Canada filings

Why semaglutide generics are in focus

Semaglutide is being positioned by multiple generic drugmakers as a lower-cost option for treating type 2 diabetes and obesity. In India, several companies have moved from regulatory approvals to product launches timed around the patent expiry in March 2026. In parallel, filings and guidance from companies in Canada indicate a second front for regulatory approvals and reference-market strategy. The latest updates tie together approvals, launch timelines, and early pricing signals. For investors and patients, the key question is how quickly supply and competition scale across markets.

India’s approval and launch cycle around March 2026

Regulatory milestones in India have stacked up over recent months, with approvals for semaglutide formulations for chronic weight management and type 2 diabetes. Multiple clearances were reported across September to December 2025, covering both bulk drug and finished formulations. These approvals set the stage for launches planned after the patent expiry in March 2026. The Indian market has also become an early indicator for how aggressively companies price semaglutide therapies once competition begins. The rollout is not limited to a single company or a single indication.

Sun Pharma: DCGI approvals and two branded launches

Sun Pharmaceutical Industries said it received approval from the Drugs Controller General of India (DCGI) to manufacture and market a generic semaglutide injection for chronic weight management. The company’s announcement date was January 23, 2026. Sun Pharma said it would launch the product under the brand name Noveltreat after the expiry of semaglutide’s patent in India. Noveltreat is offered in five dose strengths: 0.25 mg/0.5 mL, 0.5 mg/0.5 mL, 1 mg/0.5 mL, 1.7 mg/0.75 mL, and 2.4 mg/0.75 mL, administered once weekly via a prefilled pen, with 2.4 mg as the maintenance dose. Sun Pharma also received DCGI approval in December 2025 for semaglutide injection for adults with insufficiently controlled type 2 diabetes, to be launched under the brand name Sematrinity after patent expiry.

Sun Pharma’s India launch date and therapy-cost ranges

On March 21, 2026, Sun Pharma announced the launch of Noveltreat (weight management) and Sematrinity (type 2 diabetes) in India. The company said monthly therapy costs range from about ₹900 to ₹2,000 for Noveltreat and ₹750 to ₹1,300 for Sematrinity. These price points are among the clearest publicly stated affordability signals in the generic semaglutide market from a major Indian drugmaker. Sun Pharma has not specified an individual product price in the approval-related disclosures, but it has disclosed the therapy cost ranges after launch.

Dr. Reddy’s: Obeda pricing and a key regulatory milestone

Dr. Reddy’s Laboratories has already launched its generic semaglutide brand Obeda in India. Obeda is priced at ₹4,200 per month (approximately US $16-$17). The product was also described as the first semaglutide injection in the country to receive approval from the Drugs Controller General of India (DCGI). Alongside pricing, the approval milestone matters because it sets an early regulatory precedent for other domestic manufacturers targeting injectable semaglutide.

Other Indian players and manufacturing for non-patent markets

Beyond Sun Pharma and Dr. Reddy’s, the broader set of Indian companies pursuing generic semaglutide includes Zydus Lifesciences and Alkem Laboratories, with additional companies expected to launch generic versions by March. The information available also states that Sun Pharma and Dr. Reddy’s started manufacturing and exporting generic semaglutide to non-patent markets after receiving a nod from the Delhi High Court in December 2025. This adds an export angle to what might otherwise be viewed as an India-only story, and it suggests some production readiness ahead of wider commercial launches.

Canada angle: Taro’s semaglutide filing and parent linkage

Health Canada records show Taro filed its Abbreviated New Drug Submission (ANDS) for semaglutide in June 2025. Taro has not revealed a projected Canadian launch date in the available information. But its parent company launched semaglutide generics in India on March 21, 2026, linking the Canada filing to an operating playbook already visible in India. For regulatory watchers, the ANDS timing indicates the company has been preparing its Canadian pathway well ahead of expected approvals.

Aspen’s Canada strategy: dual submissions, expected timing, and manufacturing

Aspen filed a generic semaglutide submission in August 2025, followed by a second submission in February 2026. Aspen CEO Stephen Saad told Reuters the company expects to receive Canadian regulatory approval in late Q2 or Q3 of 2026 and aims to launch soon after. Aspen will manufacture the drug at facilities in South Africa and France. The company also said Canada will act as a reference market for emerging countries, indicating that the Canadian approval could support a broader rollout strategy beyond a single geography.

Market impact: affordability signals and competitive positioning

In India, early therapy-cost disclosures from Sun Pharma and the monthly price disclosed for Dr. Reddy’s Obeda show that competition is being framed around affordability and access. The coexistence of weight management and diabetes-focused brands also indicates a segmented branding approach, even though the active ingredient is the same. For pharma companies, DCGI approvals and court-related permissions to manufacture and export expand optionality across domestic and non-patent markets. In Canada, the sequence of filings and the late Q2 or Q3 2026 approval expectation for Aspen suggest a defined regulatory calendar that markets can track. The presence of multiple filers also raises the likelihood of more than one generic entrant, though exact launch timing remains company-dependent.

Key facts snapshot

Stock and investor watchpoints from the disclosures

Sun Pharma was reported trading at ₹1,636.40 on the NSE, up ₹0.50 (0.03%), as of 2:26 PM IST on January 23, 2026. While this single data point does not capture a trend, it provides a timestamped market reference linked to the DCGI approval disclosure. From an investor standpoint, the more durable watchpoints in the available information are launch dates, stated therapy-cost ranges, and regulatory timelines in Canada. The Canada filings by Taro and Aspen also introduce a multi-market narrative that extends beyond India’s patent-expiry window.

Conclusion

The semaglutide generic landscape is moving quickly across two key tracks: India’s post-approval launches around March 2026 and Canada’s regulatory pipeline built on filings from mid-2025 onward. Sun Pharma’s March 21, 2026 launches and its disclosed monthly therapy-cost ranges provide one of the clearest early pricing benchmarks, while Dr. Reddy’s Obeda adds another reference point at ₹4,200 per month. In Canada, Taro’s June 2025 ANDS filing and Aspen’s expectation of approval in late Q2 or Q3 2026 set up the next set of milestones investors and industry watchers will track. The next confirmed catalyst in the available information is Aspen’s targeted Canadian approval window and any company announcements that convert filings into launch schedules.